Open Label Extension in Adults With Binge Eating Disorder (BED)
Status:
Completed
Trial end date:
2014-10-21
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or
70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults